CVC Capital Partners ("CVC") today announced that Fred Hassan will be appointed as chairman of the international women's health assets which CVC Fund VI agreed to acquire from Teva Pharmaceutical Industries Ltd on 17th September 2017, subject to receipt of regulatory approvals.

CVC has also announced that, following closing of the transaction, the new business will be renamed Theramex. The Theramex brand has enjoyed a long heritage in women's health, with strong resonance among patients, practitioners and with many of the current employees.

Mr Hassan was chairman of the board and CEO of Schering-Plough Corporation from 2003 to 2009. Before joining Schering-Plough, Mr Hassan also served as president and CEO of Pharmacia Corporation from its creation in 2000, and has held other senior positions with Wyeth and Sandoz Pharmaceuticals. He was also a partner and managing director at Warburg Pincus LLC from 2011-2017 and prior to that served as senior advisor from 2009 to 2010.

On 10th October 2017, CVC also announced that Anish Mehta has joined Theramex as CEO. Mr Mehta joins from Allergan Plc, where he was the head of international business development. Before joining Allergan, he held a series of senior executive roles with Actavis and Watson Pharmaceuticals where he was responsible for commercial operations across Europe and the Middle East.

Fred Hassan said: "I am really looking forward to joining Theramex at such an exciting point in the company's history. I have worked in the healthcare sector for several decades and believe that now is the perfect time to address the increasing number of women's health issues. I look forward to working, together with Anish and our employees, to establish Theramex as the leading global platform for women's health products."

Cathrin Petty, partner and head of European Healthcare at CVC, added: "We are absolutely delighted that Fred has decided to join the board of Theramex. His stellar track record and vast experience in both the healthcare sector and leadership roles will be invaluable to Theramex going forward as the company looks to increase its portfolio and global presence."